Suppr超能文献

微透析和纳米过滤允许在超饱和配方的仿生溶解测试中区分分子溶解和胶体相关药物浓度。

Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations.

机构信息

Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.

Roche Pharmaceutical Research & Early Development, Pre-Clinical CMC, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

出版信息

Eur J Pharm Sci. 2022 Jul 1;174:106166. doi: 10.1016/j.ejps.2022.106166. Epub 2022 Mar 11.

Abstract

Many new drug entities are poorly water-soluble and thus require solubility-enhancing formulations to ensure sufficient bioavailability. On the other hand, it is more and more accepted that not all "dissolved" states of a drug contribute equally to enhanced absorption, i.e. an increase in apparent solubility does not necessarily go in parallel with an increase in molecularly dissolved drug, the latter being regarded as the key driving force for absorption. Our study aimed to provide time-resolved information on the dissolution, supersaturation, and precipitation behavior of molecularly dissolved drug as released from an amorphous solid dispersion and a surfactant-containing crystalline suspension of Posaconazole (PCZ), a weakly basic and poorly water-soluble drug. Thereby, we aimed to gain a deeper mechanistic understanding of enabling formulation principles and possibly establish a dynamic biopharmaceutical assessment tool for molecularly dissolved drug released from enabling formulations. A two-staged dissolution test, with media transition from simulated gastric fluid (SGF) to fasted state simulated intestinal fluid (FaSSIF), was performed with three alternative sampling approaches in parallel: the classical bench centrifugation approach was used to assess total dissolved concentrations, while a nanofiltration method and a microdialysis setup were tested for their ability to discriminate molecularly and colloid-associated drug concentrations over time. For comparison, a single-stage dissolution setup was performed, where a marketed PCZ suspension was dispersed in biomimetic media with increasing amounts of solubilizing agents to understand their effect on the concentration of molecularly dissolved drug. It was demonstrated that the microdialysis setup allowed to follow the molecularly dissolved drug concentration in a time-resolved manner during the single-and two-stage dissolution tests with marginal delays. Interestingly, the PCZ concentrations measured by the nanofiltration approach differed from both, the molecularly dissolved (assessed by microdialysis) and apparently dissolved (assessed by centrifuge) PCZ concentrations, indicating that nanofiltration may allow to differentiate between different colloid-associated (apparently) dissolved drug species. Moreover, it was shown that the release of the molecularly dissolved drug from an amorphous solid dispersion did not correlate at all with the results obtained by the centrifugation method: While this conventional sampling revealed a classical spring and parachute concentration/time-profile with a high degree of (apparent) supersaturation, the concentration of molecularly dissolved drug (assessed by the microdialysis setup) indicated an initial short decline of PCZ concentration, followed by a prolonged (moderate) molecular supersaturation. This observation may give rise to a re-thinking of the current mechanistic understanding of how amorphous solid dispersions enhance oral bioavailability. In essence, the current study provides data which indicate a benefit of both the microdialysis sampling and nanofiltration approaches for the in vitro biopharmaceutical assessment of enabling drug formulations.

摘要

许多新的药物实体水溶性差,因此需要增溶制剂来确保足够的生物利用度。另一方面,越来越多的人接受并非所有药物的“溶解”状态都同样有助于增强吸收,即表观溶解度的增加并不一定与分子溶解药物的增加平行,后者被认为是吸收的关键驱动力。我们的研究旨在提供时间分辨信息,了解从无定形固体分散体和含有表面活性剂的泊沙康唑(PCZ)结晶混悬液中释放的分子溶解药物的溶解、过饱和和沉淀行为,PCZ 是一种弱碱性和水溶性差的药物。通过这种方式,我们旨在更深入地了解使能制剂的原理,并可能为使能制剂释放的分子溶解药物建立动态生物药剂学评估工具。使用三种替代取样方法进行了两阶段溶解试验,介质从模拟胃液(SGF)过渡到空腹模拟肠液(FaSSIF):经典的台式离心法用于评估总溶解浓度,同时纳米过滤法和微透析装置用于测试其随时间区分分子和胶体相关药物浓度的能力。为了比较,还进行了单阶段溶解试验,其中将市售 PCZ 混悬液分散在具有不同增溶剂的仿生介质中,以了解它们对分子溶解药物浓度的影响。结果表明,微透析装置允许在单阶段和两阶段溶解试验中以时间分辨的方式跟踪分子溶解药物的浓度,只有轻微的延迟。有趣的是,纳米过滤法测量的 PCZ 浓度与微透析法(评估的分子溶解)和离心法(评估的表观溶解)测量的 PCZ 浓度均不同,表明纳米过滤法可能允许区分不同的胶体相关(表观)溶解药物种类。此外,结果表明,无定形固体分散体中分子溶解药物的释放与离心法的结果完全没有相关性:虽然这种常规采样显示出具有高(表观)过饱和度的经典弹簧和降落伞浓度/时间曲线,但分子溶解药物的浓度(通过微透析装置评估)表明 PCZ 浓度最初短暂下降,随后长时间(适度)分子过饱和。这一观察结果可能引发对无定形固体分散体如何增强口服生物利用度的当前机制理解的重新思考。本质上,本研究提供的数据表明,微透析采样和纳米过滤方法都有助于使能药物制剂的体外生物药剂学评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验